PMID- 31586182
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20200727
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 105
IP  - 1
DP  - 2020 Jan 1
TI  - Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic 
      Neuroendocrine Tumors < 2 Centimeters.
LID - dgz007 [pii]
LID - 10.1210/clinem/dgz007 [doi]
AB  - PURPOSE: Pancreatic neuroendocrine tumors (pNETs) are frequent in multiple 
      endocrine neoplasia type 1 (MEN1) syndrome. They are usually not surgically 
      treated unless larger than 1 to 2 cm or a growth rate > 0.5 cm per year. 
      Somatostatin analogues represent one of the main therapeutic options in pNETs, 
      but they have never been prospectively investigated in MEN1-related pNETs. The 
      aim of this study was to prospectively evaluate the effectiveness of lanreotide 
      in patients with MEN1-related pNETs < 2 cm. METHODS: MEN1 patients with 1 or more 
      pNETs < 2 cm of maximal diameter were considered. Study design was prospective 
      observational, comparing patients treated with lanreotide autogel 120 mg every 28 
      days (LAN group) and patients in active surveillance, not receiving any therapy 
      (AS group). RESULTS: Forty-two patients were enrolled: 23 in LAN and 19 in AS 
      group. Median follow-up was 73 months. Initial imaging identified a total of 91 
      pNETs. The median progression-free survival was significantly longer in the LAN 
      than in the AS group (median not reached vs 40 months, P < 0.001). In the LAN 
      group, 4 patients had an objective tumor response, 15 patients had stable 
      disease, while 4 had tumor progression. In the AS group, 13 patients had pNET 
      progression, while 6 were stable. CONCLUSIONS: This is the first prospective 
      study evaluating the efficacy of somatostatin analogues in MEN1-related pNETs. 
      These findings highlight that lanreotide autogel is effective as 
      antiproliferative therapy in MEN1-related pNETs < 2cm, suggesting the utility of 
      somatostatin analogues to arrest the development of tumor lesions as well as to 
      delay or avoid pancreatic surgery.
CI  - (c) Endocrine Society 2019. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Faggiano, Antongiulio
AU  - Faggiano A
AD  - Department of Experimental Medicine, Division of Endocrinology, Sapienza 
      University of Rome, Rome, Italy.
FAU - Modica, Roberta
AU  - Modica R
AD  - Department of Clinical Medicine and Surgery, Division of Endocrinology, 
      University Federico II of Naples, Naples, Italy.
FAU - Lo Calzo, Fabio
AU  - Lo Calzo F
AD  - Department of Clinical Medicine and Surgery, Division of Endocrinology, 
      University Federico II of Naples, Naples, Italy.
FAU - Camera, Luigi
AU  - Camera L
AD  - Department of Advanced Biomedical Sciences, Radiology, Section of Diagnostic 
      Imaging, University Federico II of Naples, Naples, Italy.
FAU - Napolitano, Vincenzo
AU  - Napolitano V
AD  - Endoscopic Surgery, Universita della Campania L. Vanvitelli, Naples, Italy.
FAU - Altieri, Barbara
AU  - Altieri B
AD  - Department of Clinical Medicine and Surgery, Division of Endocrinology, 
      University Federico II of Naples, Naples, Italy.
FAU - de Cicco, Federica
AU  - de Cicco F
AD  - Department of Clinical Medicine and Surgery, Division of Endocrinology, 
      University Federico II of Naples, Naples, Italy.
FAU - Bottiglieri, Fialomena
AU  - Bottiglieri F
AD  - Department of Clinical Medicine and Surgery, Division of Endocrinology, 
      University Federico II of Naples, Naples, Italy.
FAU - Sesti, Franz
AU  - Sesti F
AD  - Department of Experimental Medicine, Division of Endocrinology, Sapienza 
      University of Rome, Rome, Italy.
FAU - Badalamenti, Giuseppe
AU  - Badalamenti G
AD  - Department of Surgical, Oncological and Oral Sciences, Section of Medical 
      Oncology, University of Palermo, Palermo, Italy.
FAU - Isidori, Andrea M
AU  - Isidori AM
AD  - Department of Experimental Medicine, Division of Endocrinology, Sapienza 
      University of Rome, Rome, Italy.
FAU - Colao, Annamaria
AU  - Colao A
AD  - Department of Clinical Medicine and Surgery, Division of Endocrinology, 
      University Federico II of Naples, Naples, Italy.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Peptides, Cyclic)
RN  - 0G3DE8943Y (lanreotide)
RN  - 51110-01-1 (Somatostatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Case-Control Studies
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/*complications
MH  - Neuroendocrine Tumors/*drug therapy/etiology/pathology
MH  - Pancreatic Neoplasms/*drug therapy/etiology/pathology
MH  - Peptides, Cyclic/*therapeutic use
MH  - Prognosis
MH  - Prospective Studies
MH  - Somatostatin/*analogs & derivatives/therapeutic use
MH  - Tumor Burden
MH  - Watchful Waiting/*statistics & numerical data
MH  - Young Adult
OTO - NOTNLM
OT  - MEN1
OT  - active surveillance
OT  - lanreotide
OT  - pancreatic neuroendocrine tumors
OT  - somatostatin analogues
EDAT- 2019/10/06 06:00
MHDA- 2020/07/28 06:00
CRDT- 2019/10/06 06:00
PHST- 2019/06/14 00:00 [received]
PHST- 2019/09/30 00:00 [accepted]
PHST- 2019/10/06 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2019/10/06 06:00 [entrez]
AID - 5581637 [pii]
AID - 10.1210/clinem/dgz007 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2020 Jan 1;105(1):dgz007. doi: 10.1210/clinem/dgz007.